👀 Copy Legendary Investors' Portfolios in One ClickCopy For Free

Graft Polymer unveils early encouraging results from PTSD research

Published 11/12/2024, 07:29
Updated 11/12/2024, 07:40
© Reuters.  Graft Polymer unveils early encouraging results from PTSD research

Graft Polymer (UK) PLC (LSE:GPL) has announced encouraging initial findings from a pre-clinical study of AW21003, a compound being developed with Awakn Life Sciences to treat trauma-related mental health conditions like Post-Traumatic Stress Disorder (PTSD).

The research, conducted by the University of Nottingham, is part of a collaboration launched earlier this year focusing on aminoindanes, a class of compounds that may enhance pro-social behaviours such as trust and empathy, which are vital for overcoming PTSD.

Unlike MDMA, which has shown side effects such as repetitive movements in tests, AW21003 demonstrated a potentially safer profile without these behaviours.

One key finding was that animals treated with AW21003 showed an improved ability to learn and retain information, evidenced by choosing a demonstrated correct diet.

This suggests the new molecule may foster learning and social interaction, which are critical for recovery from PTSD. Researchers also observed unique behavioural patterns in treated animals, warranting further study.

To build on these results, the programme will synthesise additional aminoindane compounds, screen them for effects on brain chemicals like serotonin and dopamine, and continue testing with Nottingham researchers.

Professor David Nutt, Senior Scientific Advisor to Graft, said: "These findings represent an important milestone for our aminoindane programme.

"Developing compounds that combine therapeutic efficacy with improved safety has transformative potential for treating PTSD and other trauma-related conditions."

PTSD affects an estimated 20 million people across the US, UK, and Europe.

Read more on Proactive Investors UK

Disclaimer

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.